EMEA-001573-PIP01-13
Key facts
| Active substance |
(R)-2-[3-({Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl)phenoxy]butanoic acid
|
| Therapeutic area |
Cardiovascular diseases
|
| Decision number |
P/0222/2014
|
| PIP number |
EMEA-001573-PIP01-13
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Reduction of residual cardiovascular events in patients with diabetes
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Kowa Research Europe Ltd
|
| Decision type |
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)
|